Sato Pharmaceutical and Eisai said on March 4 that they have agreed to terminate the joint promotion of the oral antifungal agent Nailin (fosravuconazole), a treatment for onychomycosis, at the end of March this year. In Japan, the two companies…
To read the full story
Related Article
- Eisai Hands Over Fosravuconazole Rights in Asia/Oceania to Sato
July 17, 2024
- Sato, Eisai to Copromote Oral Onychomycosis Drug
October 4, 2017
BUSINESS
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





